Prolongation of PFS and OS after 5 years has been shown for 19% and 34% of melanoma patients with BRAF V600E and V600K mutations when treated with dabrafenib plus trametinib (COMBI-d and COMBI-v) [15•] and for 14% and 31% of patients with V600E-mutated melanoma treated with cobimetinib plus vemurafenib (coBRIM) [16•], respectively. Here, BRAF is linked to melanoma.